Can a tiny dose of IL-2 tame hay fever? new trial explores
NCT ID NCT03776643
First seen Nov 01, 2025 · Last updated Jun 15, 2026 · Updated 36 times
Summary
This study tested whether a low dose of IL-2, a protein that helps calm the immune system, could reduce nasal symptoms in people with birch pollen allergy. Twenty-four adults with a history of seasonal hay fever received either the drug or a placebo and were then exposed to birch pollen in a controlled chamber. The main goal was to see if the treatment eased nasal congestion during exposure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC RHINOCONJUNCTIVITIS TO BIRCH POLLEN are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CIC Biothérapies - Service de Biothérapies
Paris, Groupe Hospitalier Pitié-Salpêtrière 47 -83 BD de L'hopital, 75013, France
-
Centre d'essais cliniques, ALYATEC
Strasbourg, Environmental Exposure Chamber, Alyatec, 1 Place de L'hôpital, 67000, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.